Named Athena, it combines multiple LLMs with human-in-the-loop control

Great Falls, Montana and Kyiv, Ukraine – Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announces the launch of Athena, an AI-driven clinical localization and translation workbench designed specifically for the life sciences, healthcare, and pharmaceutical industries. Unlike standard translation engines, Athena provides an adaptive, guided, and fully transparent process to provide high-quality, regulatory-compliant translations that enhance both speed and accuracy.

Built to meet the needs of eCOA providers, clinical trial site and recruitment organizations, and clinical research organizations (CROs), Athena serves as a best-in-class AI-powered workbench that combines multiple large language models (LLMs). Athena maintains human-in-the-loop control to ensure the highest translation quality in a guided, not automated experience.

“My partners and I set out to build a tool that we needed – that our industry needs – to truly solve the challenges of clinical translation and localization,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Athena is our answer. This is the only workbench of its kind that is designed to empower expert translators with AI-driven support, guided parsing, and full workflow automation. You can’t rely solely on machines in the life sciences industry, but with Athena, we are making it easier to achieve accuracy, consistency, and compliance at an unexpected pace.”

Key Differentiators That Set Athena Apart

Athena by Cliniphai combines AI-driven efficiency with human expertise, delivering a guided, adaptive, and compliance-focused translation experience tailored for life sciences. Key differentiators include the following:

• Adaptive and Context-Aware Translations: Athena understands dialects, terminology, and context, and it gives users the ability to add instructions, choose available dialects, simplify language, and maintain consistency across large-scale projects.
• Auto-Review: Athena automates the guidance and management process, maintaining tone, terminology, and compliance.
• Accelerated Rescue Translations: Athena is designed to compress timelines and handle high-stakes, large-scale translation projects on tight turnarounds.
• Best-in-Class Service: Built with clever integration of proprietary AI-enabled services on top of industry leading workflow management, Athena can operate with scale to ensure smooth project handling, customer support, and compliance.
• Powered by Real-World Expertise: Cliniphai has built deep operational experience across clinical studies and is working with trusted partners that have spent decades ensuring linguistic accuracy in life sciences.
• Seamless API Integration: Fully accessible via API, Cliniphai allowing life sciences companies to integrate Athena directly into their existing platforms, workflows, and regulatory processes.
• On-Premise Deployment for Maximum Security: Athena can be installed directly within your organization’s infrastructure, allowing you to maintain complete control over data, eliminate external communication delays, and integrate seamlessly with your existing workflows and processes.

A new standard for translations

Cliniphai’s globally-located team speaks more than 10 languages in-house, bringing a global perspective to clinical and regulatory translation challenges. Additionally, the company’s 17-person development team is actively refining the software development lifecycle and using AI, combined with the proper scientific acumen, to exceed industry expectations.

“Poor translations have led to millions in lawsuits in our industry, and Cliniphai is committed to ensuring this never happens to its customers. No matter the translation or localization need, it shouldn’t be a slow, painful process. So far, the feedback from our testing group has been very positive,” added Vladimir Mats, PhD, CEO and Co-Founder, Cliniphai. “Our goal from day one was to redefine clinical translation and localization workflows for the pharmaceutical and biotech industry, and today it becomes a reality.”

Martin added, “The team explored multiple entry points as an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, and after various prototypes, we decided to build translation and localization first. This is simply the beginning, and Cliniphai’s future is very bright.”

Ask for a demonstration of Athena by Cliniphai at www.cliniphai.com.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences that accelerates innovation, streamlines operations, and enables smarter decision-making across the entire value chain. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization tool focused on delivering secure, compliant, and high-quality solutions for life sciences. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences—without compromising accuracy, security, or compliance. For more information, visit: https://www.cliniphai.com/.

MMS, an award-winning, data-focused clinical research organization (CRO), announced today its acquisition of Exploristics, a leading biostatistics and data science company based in Belfast, Northern Ireland. The acquisition will add the company’s flagship product, KerusCloud®, a state-of-the-art, cloud-based statistical modeling and simulation platform to MMS’ data-driven approach towards efficient drug development.

With a history of strong organic growth, the acquisition of Exploristics positions MMS to enhance its global footprint and capabilities in advanced clinical trial design, innovative statistics, and data science. Building on its excellent track record in regulatory and end-game submissions, this acquisition now solidifies MMS as the leader in biometrics and development strategy solutions for biotechnology and pharmaceutical sponsors of all sizes.

“We are proud to bring the Exploristics team into the #OneMMS family,” said Dr. Uma Sharma, CEO, MMS. “When exploring acquisition opportunities to enhance our strategic capabilities as a leading data CRO, we sought organizations that would complement our existing regulatory approach and build a powerful combination of regulatory and statistical design expertise, combined with market-leading study simulation software. We found that in Exploristics, along with a like-minded culture.”

Chris Schoonmaker, Chief Operating Officer at MMS, added, “Exploristics joining MMS is an exceptional fit, and we look forward to delivering even greater value to our clients through optimized strategies that reduce the overall time and cost burden in drug development.”

Expanding Expertise and Global Reach in Europe

The acquisition of Exploristics by MMS aligns with the company’s focus on broadening its data-focused solutions to enhance the ability to simulate, analyze, and optimize studies, as well as reduce risk and drive efficiencies. By combining the two organizations’ strengths, MMS will now provide:

• Advanced statistical design and data science capabilities across diverse therapeutic areas and study types.
• Enhanced and real-time pivots for orphan, rare, and special disease populations with an unmet medical need.
• Study simulation and development planning with the integration of KerusCloud into an existing award-winning technology suite that boasts a 3x increase in development program success rates and up to USD 20 million saved on a single study.
• Expanded global presence, with increased scale in Europe and access to a highly skilled team of biostatisticians and data scientists.

“Joining MMS represents an exciting new chapter for Exploristics,” said Aiden Flynn, Founder and CEO of Exploristics, now Senior Vice President, Head of Strategic Statistical Consulting at MMS. “Our ethos has always centered on openness, honesty, professionalism, flexibility, and creativity—qualities that I’ve experienced at MMS since day one of our discussions. I am confident that our employees, partners, and clients will benefit from this partnership as we amplify our impact and expand our global reach.”

Ben Dudley, Chief Commercial Officer at MMS, added “Our presence in Europe has seen significant growth in recent years, and this acquisition adds to our vitality in the region. Our focus on data for better trial data execution, lower risk, stronger submissions, integration of Real-World Data (RWD) into clinical outputs and accelerated outcomes has never been stronger than it is today.”

Learn more about MMS at https://www.mmsholdings.com.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com

About Exploristics

Exploristics is a world-leading technology-enabled services company that transforms clinical development for life sciences organizations with unique proprietary software and biostatistics consultancy supporting the planning, design, and analysis of clinical studies.

About KerusCloud®

KerusCloud, an MMS technology, is a revolutionary simulation-guided study design tool that ensures clinical trials are designed effectively to collect the right data, in the right patients, in the right way. Its use supports evidence-based design decisions to extensively de-risk real clinical studies, reducing development times, costs, and patient burden.